Livedoid vasculopathy in a patient with lupus anticoagulant and MTHFR mutation: treatment with low-molecular-weight heparin

被引：11

作者：

Abou Rahal, Jihane ^{[1
]}

Ishak, Rim S. ^{[2
]}

Otrock, Zaher K. ^{[1
]}

Kibbi, Abdul-Ghani ^{[2
]}

Taher, Ali T. ^{[1
]}

机构：

[1] Amer Univ Beirut, Med Ctr, Dept Internal Med, Div Hematol Oncol, Beirut 11072020, Lebanon

[2] Amer Univ Beirut, Med Ctr, Dept Dermatol, Beirut 11072020, Lebanon

来源：

JOURNAL OF THROMBOSIS AND THROMBOLYSIS | 2012年 / 34卷 / 04期

关键词：

Livedoid vasculopathy; Hypercoagulable state; MTHFR; Lupus anticoagulant; Low-molecular-weight heparin; Treatment; PROTHROMBIN G20210A; HETEROZYGOSITY; HOMOZYGOSITY; DISEASE;

D O I：

10.1007/s11239-012-0743-5

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Livedoid vasculopathy is characterized by painful purpuric lesions on the extremities which frequently ulcerate and heal with atrophic scarring. For many years, livedoid vasculopathy has been considered to be a primary vasculitic process. However, there has been evidence considering livedoid vasculopathy as an occlusive vasculopathy due to a hypercoagulable state. We present the case of livedoid vasculopathy in a 21-year-old female who had been suffering of painful lower extremity lesions of 3 years duration. The patient was found to be lupus anticoagulant positive and homozygous for methylenetetrahydrofolate reductase C677T mutation. The patient was successfully treated with low-molecular-weight heparin.

引用

页码：541 / 544

页数：4

共 11 条

[1] Livedoid Vasculopathy Associated with Plasminogen Activator Inhibitor-1 Promoter Homozygosity (4G/4G) and Prothrombin G20210A Heterozygosity: Response to t-PA Therapy
Antunes, Joana
Filipe, Paulo
Andre, Marisa
Fraga, Ana
Miltenyi, Gabriel
Gomes, Manuel Marques
[J]. ACTA DERMATO-VENEREOLOGICA, 2010, 90 (01) : 91 - 92
[2] Livedoid vasculopathy and hypercoagulability in a patient with primary Sjogren's syndrome
Cardoso, Raquel
Goncalo, Margarida
Tellechea, Oscar
Maia, Rosa
Borges, Catarina
Silva, J. A. Pereira
Figueiredo, Americo
[J]. INTERNATIONAL JOURNAL OF DERMATOLOGY, 2007, 46 (04) : 431 - 434
[3] Livedoid vasculopathy as a coagulation disorder
Criado, Paulo Ricardo
Rivitti, Evandro Ararigboia
Sotto, Mirian Nacagami
de Carvalho, Jozelio Freire
[J]. AUTOIMMUNITY REVIEWS, 2011, 10 (06) : 353 - 360
[4] Frequency of thrombophilia determinant factors in patients with livedoid vasculopathy and treatment with anticoagulant drugs - a prospective study
Di Giacomo, T. B.
Hussein, T. P.
Souza, D. G.
Criado, P. R.
[J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2010, 24 (11) : 1340 - 1346
[5] Difficult management of livedoid vasculopathy
Francès, C
Barete, S
[J]. ARCHIVES OF DERMATOLOGY, 2004, 140 (08) : 1011 - 1011
[6] Livedoid Vasculopathy in a Pediatric Patient With Elevated Lipoprotein(a) Levels: Prompt Response to Continuous Low-Molecular-Weight Heparin
Goerge, Tobias
Weishaupt, Carsten
Metze, Dieter
Nowak-Goettl, Ulrike
Sunderkoetter, Cord
Steinhoff, Martin
Schneider, Stefan W.
[J]. ARCHIVES OF DERMATOLOGY, 2010, 146 (08) : 927 - 928
[7] Treatment of livedoid vasculopathy with low-molecular-weight heparin - Report of 2 cases
Hairston, BR
Davis, MDP
Gibson, LF
Drage, LA
[J]. ARCHIVES OF DERMATOLOGY, 2003, 139 (08) : 987 - 990
[8] Livedoid vasculopathy associated with combined prothrombin G20210A and factor V (Leiden) heterozygosity and MTHFR C677T homozygosity
Irani-Hakime, Noha A.
Stephan, Farid
Kreidy, Raghid
Jureidini, Isabelle
Almawi, Wassim Y.
[J]. JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2008, 26 (01) : 31 - 34
[9] Livedoid vasculopathy: thrombotic or inflammatory disease?
Khenifer, S.
Thomas, L.
Balme, B.
Dalle, S.
[J]. CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2010, 35 (07) : 693 - 698
[10] Atrophie blanche
Maessen-Visch, MB
[J]. EUROPEAN JOURNAL OF OBSTETRICS GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2000, 90 (01): : 1 - 2

← 1 2 →